Report revives lingering rumor of a looming GSK bid for Theravance; Struggling Vivus grabs $110M loan;

 @FierceBiotech: From FierceBiotechResearch.com: Researchers find possible cause of neuron dysfunction in Alzheimer's. Article | Follow @FierceBiotech

 @JohnCFierce: Another one bites the dust: Phytopharm slashes staff, scouts buyers after Parkinson's drug failure. Story | Follow @JohnCFierce

 @RyanMFierce: The top 10 moneymakers in Pharma, ordered by revenue and described in context: More | Follow @RyanMFierce

> Over the weekend, Bloomberg revived persisting rumors that GlaxoSmithKline ($GSK) was getting ready to buy out Theravance, its partner on a pair of key new drugs called Breo and Anoro. Both therapies have been pegged as likely winners at the FDA, though several analysts have cautioned on their chances in a crowded field. But with Theravance revenues pointed up, GSK may not be able to resist the urge of a takeover. It should be said, though, that this particular rumor has lingered for some time. Story

> Vivus ($VVUS) has raised $110 million in new financing from a fund managed by Pharmakon Advisers. Vivus has an option to draw down the first $50 million now and the rest of the money as needed. Vivus has been struggling in its effort to sell a new weight drug. Release

> Novartis says the FDA has OK'd its TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa bacteria in the lungs. Story

Pharm​a News

 @FiercePharma: Pfizer tuberculosis drug hits FDA shortage list, with other TB remedies already scarce. Story | Follow @FiercePharma

 @EricPFierce: Momenta's Kaundinya doesn't mind some regulatory chaos in biosimilars. It allows industry to help shape pathway. Special Report | Follow @EricPFierce

> Eli Lilly CEO's pay package slides 11% to $14.6M. More

> Despite sales slide, Bristol-Myers CEO nabs 15% raise to $17.2M. Story

Medical Device News

 @FierceMedDev: Merck IUD lot hit with Hong Kong recall. Report | Follow @FierceMedDev

 @MarkHFierce: A multi-gene sequencing cancer Dx test is hitting the U.K. health system, thanks to the NHS. More | Follow @MarkHFierce

 @DamianFierce: Researchers at the Cleveland Clinic are developing a breath-based diagnostic to detect heart failure. Story | Follow @DamianFierce

> PrimeraDx teams with Quest for companion diagnostics. More

> TriReme allies with major China distributor for PAD devices. Story

> J&J recalls LifeScan glucose meters over shutdown risk. Report

Pharma Manufacturing News

> FDA fast-tracks plant for injectable on shortage list. More

> India state ups effort to root out counterfeits. Story

> Form 483 lays out latest issues dragging down Hospira. Report

> Sanofi, Transgene split cost of specialized manufacturing. Article

> Actavis puts $40M into Florida plant. More

Biotech Research News

 @EmilyMFierce: Could a canker sore treatment be the next weight-loss drug? More | Follow @EmilyMFierce

> UMD scientists test new bird flu vaccine in animals. Report

> Astellas strikes deals to hunt for dengue fever therapies. More

> New database could be a boon for genomics research. Story

> Tiny wireless sensor moves brain research forward. Item

And Finally…A new study from Tufts investigators has spotlighted the "unique resistance mechanisms of a clinical isolate of E. coli" to antibiotics. Release

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.